Sanofi (NASDAQ:SNY) Shares Purchased by McClarren Financial Advisors Inc.

McClarren Financial Advisors Inc. raised its position in Sanofi (NASDAQ:SNY) by 952.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 600 shares of the company’s stock after buying an additional 543 shares during the period. McClarren Financial Advisors Inc.’s holdings in Sanofi were worth $28,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after acquiring an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors lifted its stake in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after purchasing an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares during the period. Finally, GFS Advisors LLC increased its stake in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after purchasing an additional 11,655 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Price Performance

Shares of Sanofi stock opened at $54.56 on Thursday. The business’s fifty day moving average price is $50.07 and its 200 day moving average price is $52.41. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $138.46 billion, a P/E ratio of 21.91, a PEG ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.